Results 151 to 160 of about 926 (182)
Some of the next articles are maybe not open access.
Neuroprotective potential of saroglitazar in
AbstractParkinson's disease (PD) is a neurodegenerative disorder that affects 2%–3% of the population worldwide. Clinical presentation of PD includes motor and non‐motor symptoms. The interplay between pathogenic factors such as increased oxidative stress, neuroinflammation, mitochondrial dysfunction and apoptosis are responsible for neurodegeneration ...
Rohit Bhatt +10 more
openaire +2 more sources
Saroglitazar reduces obesity and associated inflammatory consequences in murine adipose tissue
European Journal of Pharmacology, 2018Prevailing knowledge links chronic low-grade inflammation in the adipose tissue to obesity and its associated metabolic complications. In this study, we evaluated immunometabolic effects of a recently launched dual peroxisome proliferator-activated receptor (PPAR) α & γ agonist 'Saroglitazar' in a mouse model of diet-induced obesity (DIO).
Durgesh, Kumar +10 more
openaire +2 more sources
474-P: Efficacy of Saroglitazar on Diabetes Dyslipidemia with Higher Triglyceride
Diabetes, 2022Objectives: Diabetes and diabetic dyslipidemia with high triglycerides (TGs) are commonly associated. Saroglitazar is the first dual PPAR α/γ agonist which has been approved in India for diabetes dyslipidemia management. This study aimed at evaluation of the efficacy and long-term safety of Saroglitazar on diabetic dyslipidemia with very high ...
openaire +1 more source
Virtual identification of novel PPARα/γ dual agonists by scaffold hopping of saroglitazar
Journal of Biomolecular Structure and Dynamics, 2017The thiazolidinedione class PPARγ agonists as antidiabetic agents are restricted in clinical use because of the side effects such as edema, weight gain, and heart failure. The single and selective agonism of PPARγ is the main cause of side effects.
Wen-Qing, Jia +8 more
openaire +2 more sources
Effect of Saroglitazar on Liver Stiffness and Liver Enzymes in Nafld
Journal of Clinical and Experimental Hepatology, 2022Krishnadas Devadas +2 more
openaire +1 more source
Inflammopharmacology
Drug repurposing has emerged as a cost-efficient strategy for neurodegenerative disorders (NDDs), leveraging existing preclinical, safety, and tolerability data to identify therapeutic candidates. NDDs, including epilepsy, Parkinson's disease (PD), Alzheimer's disease (AD), and traumatic brain injury (TBI), are characterized by neuroinflammation ...
Shiv Kumar Kushawaha +4 more
openaire +2 more sources
Drug repurposing has emerged as a cost-efficient strategy for neurodegenerative disorders (NDDs), leveraging existing preclinical, safety, and tolerability data to identify therapeutic candidates. NDDs, including epilepsy, Parkinson's disease (PD), Alzheimer's disease (AD), and traumatic brain injury (TBI), are characterized by neuroinflammation ...
Shiv Kumar Kushawaha +4 more
openaire +2 more sources
Effect of dual PPAR-α/γ agonist saroglitazar on diabetic retinopathy and oxygen-induced retinopathy
European Journal of Pharmacology, 2021Amit Joharapurkar +2 more
exaly
Study of Saroglitazar in Treatment Of Pre-diabetes with Dyslipidemia: STOP-D.
The Journal of the Association of Physicians of India, 2019Patients with prediabetes are not only at increased risk of progression to type 2 diabetes, but they are also at high risk of developing cardiovascular risk compared to normoglycemic people. Further, prediabetes is also often associated with abnormal lipid levels (dyslipidemia). We therefore aimed to evaluate the effect of Saroglitazar in patients with
Deepak, Bhosle +5 more
openaire +1 more source